Safety, Tolerability and Pharmacokinetics of SBC-102 (Sebelipase Alfa) in Adult Participants With Lysosomal Acid Lipase Deficiency

NCT01307098 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

9

Enrollment

INDUSTRY

Sponsor class

Conditions

Cholesterol Ester Storage Disease(CESD)
Lysosomal Acid Lipase Deficiency
LAL-Deficiency

Interventions

DRUG: Sebelipase alfa 0.35 mg/kg
DRUG: Sebelipase alfa 1 mg/kg
DRUG: Sebelipase alfa 3 mg/kg

Sponsor

Alexion Pharmaceuticals, Inc.